Meeder Asset Management Inc Novavax Inc Transaction History

Meeder Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.2 - $76.12 $1,183 - $4,947	-65 Reduced 76.47%	20 $0
Q2 2022 Aug 08, 2022	BUY	$36.28 - $75.29 $181 - $376	5 Added 6.25%	85 $4,000
Q1 2022 May 10, 2022	BUY	$69.73 - $142.9 $5,578 - $11,432	80 New	80 $6,000
Q4 2021 Feb 11, 2022	SELL	$134.56 - $217.97 $291,187 - $471,687	-2,164 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$177.8 - $270.58 $21,158 - $32,199	-119 Reduced 5.21%	2,164 $448,000
Q2 2021 Aug 09, 2021	BUY	$121.0 - $257.67 $54,329 - $115,693	449 Added 24.48%	2,283 $485,000
Q1 2021 Apr 28, 2021	BUY	$112.98 - $319.93 $207,205 - $586,751	1,834 New	1,834 $334,000
Q4 2020 Feb 09, 2021	SELL	$78.74 - $139.5 $162,125 - $287,230	-2,059 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$79.44 - $178.51 $53,701 - $120,672	676 Added 48.88%	2,059 $224,000
Q2 2020 Aug 11, 2020	BUY	$13.86 - $83.61 $13,471 - $81,268	972 Added 236.5%	1,383 $116,000
Q1 2020 May 15, 2020	SELL	$3.93 - $16.0 $699 - $2,848	-178 Reduced 30.22%	411 $6,000
Q4 2019 Feb 13, 2020	BUY	$3.69 - $5.22 $376 - $532	102 Added 20.94%	589 $2,000
Q3 2019 Oct 17, 2019	BUY	$4.02 - $7.84 $1,957 - $3,818	487 New	487 $2,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.